Intraday Alerts
FONT-SIZE Plus   Neg

Amgen Inc. (AMGN) Has Risen To A New High For The Year

Trade AMGN now with 

Amgen Inc. (AMGN: Quote) announced after the bell Tuesday that its Phase 3 trial of talimogene laherparepvec for the treatment of melanoma met its primary endpoint.

Amgen has been climbing for the majority of early trade Wednesday and is now up 2.32 at $94.72. The stock has risen above a 3-week range and has set a new high for the year.

Click here to receive FREE breaking news email alerts for Amgen Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback:

Business News

comments powered by Disqus